These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23114131)

  • 1. [Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
    Zhang L; Ma YP; Jia G; Lu YJ; Zhang L; Lu H; Chang MX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1122-6. PubMed ID: 23114131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y; Liu W; Zhang L; Jia G
    Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
    Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
    Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
    Jiang XX; Zhang QL; Chen XY; Wu WL; Shen ZX; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1215-9. PubMed ID: 19840453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
    Ramakrishnan V; Kimlinger T; Timm M; Haug J; Rajkumar SV; Kumar S
    Leuk Res; 2014 Nov; 38(11):1358-66. PubMed ID: 25282334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
    Ge QF; Ouyang GF; Chen Y; Zhang Y; Mu QT; Lu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):112-5. PubMed ID: 22391178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
    Catley L; Weisberg E; Kiziltepe T; Tai YT; Hideshima T; Neri P; Tassone P; Atadja P; Chauhan D; Munshi NC; Anderson KC
    Blood; 2006 Nov; 108(10):3441-9. PubMed ID: 16728695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
    Xu M; Hong M; Xie H
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct; 33(10):1409-15. PubMed ID: 24144737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
    Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
    PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
    Wu HY; Wang SM; Huang JQ; Hao LM; Li XM; Wei LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1361-4. PubMed ID: 23257433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
    Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S; Boise LH; Lee KP; Nikiforov MA
    Blood; 2012 Feb; 119(6):1450-8. PubMed ID: 22144178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells].
    Yang Y; Dong HJ; Gao GX; Wang YW; Gu HT; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):335-8. PubMed ID: 22541093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.